"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 1 | 7 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 6 | 0 | 6 |
| 2016 | 2 | 7 | 9 |
| 2017 | 13 | 2 | 15 |
| 2018 | 12 | 3 | 15 |
| 2019 | 11 | 6 | 17 |
| 2020 | 16 | 6 | 22 |
| 2021 | 9 | 4 | 13 |
| 2022 | 5 | 17 | 22 |
| 2023 | 5 | 18 | 23 |
| 2024 | 25 | 9 | 34 |
| 2025 | 28 | 6 | 34 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat Commun. 2026 Feb 04; 17(1):1349.
-
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan 13; 10(1):217-227.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
-
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026 Jan; 32(1):258-269.
-
Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells. Clin Cancer Res. 2025 Dec 15; 31(24):5137-5144.
-
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025 Dec 09; 9(23):6047-6058.
-
Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors. Nat Commun. 2025 Dec 09; 16(1):10987.
-
Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec; 23(12).
-
Advancing CAR-T cell manufacturing in Latin America: Current landscape, future directions, and challenges. Crit Rev Oncol Hematol. 2026 Jan; 217:105041.
-
Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b. Cancer Immunol Res. 2025 Nov 03; 13(11):1732-1748.